Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

HM, have you seen Renesola (SOLA)? Results due out in two days' time, and they ought to be a real cracker. It's already profitable, expanding rapidly, may be a bit risky as it is in China but has chosen to list on AIM. huge amount of potential cash generation, though. Best place for the reports and articles is FT.com (you may want to print stuff out as they don't seem to make it available for very long). It's worth having a read of the thread on this BB too (and over the road if you have a lot of time on your hands!)

Tipped by two analysts so far, each with target price of 300p; could easily be 5 - 8 between end of 2007 and mid-2008 or by the 2008 FY results.

I got in initially at 145p and increased about ten days ago at just under 200p. You could say it's may favourite stock at the mo.

PDYOR, etc.

thanks soul I'll have a look. keep em coming!

soul I actually saw SOLA a while back except I didn't jump in early enough and then saw it again below 2 and missed the chance again!!!
thats why I could do with tips before they move up so look forward to your other tips as you seem to jump in at the right time! well done!
anyways Plethora overhang has definately cleared hence the move up today so far again with a few buys which confirms that!

Honda, I don't get all my timing right - it's a case of not always having the csh to invest when I want to, plus of course we all make errors of judgment.

I do read a lot of different threads on here though, as well as doing a fair bit of research into the co's behind them.

Another nice bit of progress today though: PLE Bid: 200p Offer: 208p Change: 4

some more info showing confidence Plethora have signed a deal with Inyx to manufacture the aerosol for PSD502 for phase III trials.

So they did:

Inyx Signs Deal with Plethora Solutions to Produce Novel HFA Aerosol Indicated for the Treatment of Premature Ejaculation for Clinical Trial in the United States




NEW YORK, Nov. 2 /PRNewswire-FirstCall/ -- Inyx, Inc. , a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced today that it has signed an agreement with Plethora Solutions Holdings plc (AIM: PLE), an emerging U.K. specialty pharmaceutical company, to manufacture a topical HFA aerosol product used in the treatment of premature ejaculation (PE) for Phase III clinical trial in the United States. The production will be conducted at Inyx USA's FDA-approved site in Puerto Rico.

Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are very pleased that Inyx has been selected for the production of Plethora's PE product for the Phase III clinical trial. We are particularly delighted that a U.K.-based company has selected Inyx USA. This collaboration reflects our expertise in HFA aerosol production and our overall capabilities on both sides of the Atlantic."

Dr. Steven Powell, CEO of Plethora, commented, "We are very happy with our collaboration with Inyx, which allows us to progress PSD502 down the path towards Phase III clinical development."

Plethora's PE product, known as PSD502, is a topical agent comprised of a unique proprietary and rapidly absorbed formulation of two well established local anesthetics, dispensed by a metered dose spray.

PE is a medically recognized condition defined as "persistent or recurrent ejaculation with minimal sexual stimulation before, upon or shortly after penetration, and before the person wishes it." PE is the most common form of sexual dysfunction in men. According to the American Medical Association, approximately 20 million men in the U.S. experience PE. Since there is currently no approved pharmaceutical therapy, the PE market offers significant potential for development and growth. An effective drug therapy for PE may have a commercial potential comparable to the erectile dysfunction drug, Viagra(R), for which current annual sales are approximately $1.7 billion.



Source: http://www.wivb.com/Global/story.asp?S=5625837

or just Google it.

Good find, Hondaman, thanks very much!

some more info showing confidence Plethora have signed a deal with Inyx for them to manufacture the aerosol for PSD502 for phase III trials for Plethora.
(http://www.inyxinc.com/page420618.aspx)

Just my feeling but I am going for a deal to be announced this month.
Lets see -good luck all!! although we have been informed by RNS that it will be in second half so not long to go anyways!

from recent results -this is the interesting part for me!
" In the second half of 2006 we look forward to the continued growth of product revenues and are confident that we will add significant licensing income from PSD502 to the top line.'

Timm Medical is bringing in great revenue going by the RNS and on top will be immediate licensing revenue from PSD502.

I am going to stick with next week as news week on deal news.
Good luck all!

News can still come November 2006 -still a few days to go -otherwise December 2006 it will defo come -company have stated this in the results RNS that PSD502 will bring in SIGNIFICANT licensing revenue in 2006 .

Honda, I too am hoping that news will soon be forthcoming, but predictions of when deals will be made can be very unreliable. I'm content to wait a while if necessary; happy to get in ahead of the herd.

soul -todays news is a start of more news -thats my take and PSD502 news this year 2006 will mean a great mark up so yes its best to get in before that happens.

These relatively minor items of news are good and lift the price steadily in prelude to major news. After all, doube 2 is better than double 1.50p :o)

Plethora Solutions - Product Update PSD401
RNS Number:7197M
Plethora Solutions Holdings PLC
27 November 2006


PLETHORA SOLUTIONS HOLDINGS PLC

Product Update

PSD401 - Sexual Activity Monitor (SAMTM)
Plethora Enters Into Agreement with Global Pharmaceutical Company

Plethora Solutions Holdings plc ('Plethora' or the 'Company', AIM : PLE), the
specialist developer of products for the treatment and management of urological
disorders, today announces that it has entered into an agreement with a major
multi-national pharmaceutical company to supply Plethora's Sexual Assessment
Monitor (SAMTM, PSD401), a device for the measurement and automated recording of
ejaculation time, into a clinical programme using time to ejaculation as a
primary endpoint. The use of PSD401 to measure time to ejaculation introduces a
new level of accuracy over the traditional method of measurement using a hand
held stop watch. A similar agreement was entered into with Johnson & Johnson in
2005.

Plethora recently published the successful conclusion of development trials on
PSD401. (Dinsmore et al (2006) BJU Int, 98; 613-61). These trials, monitoring
both healthy volunteers and patients suffering from Premature Ejaculation (PE),
established the reproducibility, efficacy and safety of the product and the
ability to discriminate between healthy patients with 'normal' latency times and
PE sufferers.

Dr. Mike Wyllie, CSO of Plethora, commented; 'We are delighted that another
leading pharmaceutical company has selected PSD401 for use in their development
of treatments for sexual dysfunction. This second agreement demonstrates clearly
that PSD401 can be a valuable aid to clinical development within major
pharmaceutical companies and is a key component in our commercialisation of the
product.'

As well as working with pharmaceutical companies that utilise the product in
clinical development and marketing programmes for drugs for the treatment of PE,
PSD401 will ultimately be used by the urologists, andrologists, other relevant
specialists and primary care physicians who are responsible for the diagnosis
and management of the large PE patient population. For this purpose, Plethora
has obtained both European and US marketing approval for the device, which will
be marketed through its subsidiary, Timm Medical. The recent 510K approval for
marketing of the device should also expedite acceptance in the US as a front
line diagnostic system. In this context, many of the key sexual health opinion
leaders in the USA are to take delivery of PSD401s in Q1 2007

In the expanding sexual health market, PSD401 complements Plethora's therapeutic
product PSD502 for the treatment of PE which is about to enter phase III
clinical trials once on-going partnering discussions are finalised.


-Ends-

Definitely good news today, and that's one thing you can say about PLE, is that there is a steady trickle of good news and product updates.

A slightly muted response from the market, though - only 8,805 shares traded so far today, but I guess until the big deal comes through, this may be travelling below many poeples' radar.

PLE Bid: 198p Offer: 205p Change: 3.5

Navajo -good point
Todays news is great -they have stated that more large pharmas are to take delivery of PSD401 - means more product revenues -thats what we want to hear.
Notice they haven't stated the Pharmas name or deal amount -I wonder if its the same company who they will announce the deal for PSD502 with? interesting.

PSD401 is apparently due for many deliveries in Q1 2007.

BTW, Hondaman, since you asked me for tips: Just want to let you know I have been persuaded to join the GTL club. This is the ethanol producer - they have big plans for growth and will soon be producing far more than RVA, which currently has a bigger market cap. New plant due to start commercial production in early December; capacity will then double as they extend the plant over the following year or so, plus they want to build a further three plants. Shares Mag has tipped it consistently this year.

Prospects for growth look excellent, but please DYOR, etc.